ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,977Medicare Part D Prescriptions Filled, Including Refills

Rank: 193 out of 2094

$554K Total Retail Price of All Prescriptions

Rank: 406 out of 2094

312 Patients Receiving at Least One Drug in Part D
96%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Jersey
Lower avg

Schedule Two
Controlled Substances

19% of this provider’s 312 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 9,549 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 32%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $78 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Jersey
FUROSEMIDE 468 464 1 6
LEVOTHYROXINE SODIUM 412 412 2 3
AMLODIPINE BESYLATE 298 296 3 2
TRAZODONE HCL 282 278 4 72
WARFARIN SODIUM 264 205 5 11
LISINOPRIL 260 250 6 7
METOPROLOL TARTRATE 249 247 7 10
CITALOPRAM HBR 239 238 8 47
SIMVASTATIN 219 205 9 1
OMEPRAZOLE 207 189 10 4
NAMENDA 190 187 11 32
METOPROLOL SUCCINATE 177 177 12 9
POTASSIUM CHLORIDE 152 146 13 24
DONEPEZIL HCL 130 121 14 20
MIRTAZAPINE 130 130 14 43
RISPERIDONE 124 124 16 56
ZOLPIDEM TARTRATE 123 88 17 14
PRAVASTATIN SODIUM 115 112 18 18
SERTRALINE HCL 113 113 19 26
HYDROCHLOROTHIAZIDE 104 104 20 12
TRAMADOL HCL 101 93 21 33
OXYCODONE-ACETAMINOPHEN 100 92 S2 22 40
ATORVASTATIN CALCIUM 94 93 23 5
TAMSULOSIN HCL 93 93 24 29
GABAPENTIN 92 90 25 23
OXYCODONE HCL 87 67 S2 26 63
PANTOPRAZOLE SODIUM 86 84 27 37
ALENDRONATE SODIUM 85 85 28 30
KLOR-CON M20 74 74 29 106
DIGOXIN 73 73 30 51
LIDODERM 72 71 31 59
DIOVAN 72 70 31 13
LEVOFLOXACIN 72 71 31 70
ESCITALOPRAM OXALATE 69 68 34 46
ISOSORBIDE MONONITRATE ER 67 67 35 57
ATENOLOL 64 64 36 21
OXYCONTIN 64 64 S2 36 98
CARVEDILOL 63 50 38 19
CLOTRIMAZOLE-BETAMETHASONE 61 56 39 91
SPIRIVA 58 58 40 60
FLUTICASONE PROPIONATE 57 57 41 41
TRAVATAN Z 54 54 42 189
CYMBALTA 54 54 42 61
FENTANYL 54 54 S2 42 68
POLYETHYLENE GLYCOL 3350 52 51 45 75
HYDRALAZINE HCL 52 52 45 89
BUSPIRONE HCL 51 50 47 159
MUPIROCIN 51 51 47 117
LAMOTRIGINE 51 38 47 177
LACTULOSE 51 50 47 65
CARBIDOPA-LEVODOPA 50 50 51 102
GENERLAC 50 50 51 323
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 16, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.